Harmony Biosciences Holdings, INC Form 4 insider transactions

Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, exercised stock options and sold shares to cover income tax withholdings on May 1, 2025.

Adam H. Zaeske, Chief Commercial Officer of Harmony Biosciences Holdings, received stock options for 100,000 shares and 30,000 restricted stock units on April 7, 2025, according to a recent SEC filing.

Director Ron M. Philip of Harmony Biosciences Holdings, Inc. reports acquisition of stock options.

Harmony Biosciences CFO Sandip Kapadia executed sales of common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., reports the vesting of restricted stock units and subsequent stock sales to cover tax obligations.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences, sold shares of common stock on March 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, reports the vesting of restricted stock units and subsequent tax withholding, along with the grant of new stock options and restricted stock units.

A Harmony Biosciences executive, Jeffrey Dierks, executed multiple transactions involving the company's stock, including sales and the vesting of stock options and restricted stock units.

Harmony Biosciences CEO, Jeffrey M. Dayno, exercised stock options and received restricted stock units, resulting in changes to his beneficial ownership of company stock.

Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., reports transactions involving common stock and derivative securities, including the vesting and sale of restricted stock units.

Chief Strategy Officer of Harmony Biosciences, Andrew Serafin, reports the vesting of restricted stock units and the grant of stock options.

Harmony Biosciences CEO Jeffrey Dayno exercised stock options and sold shares of common stock on January 21, 2025, according to a Form 4 filing with the SEC.

Sandip Kapadia, CFO of Harmony Biosciences Holdings, exercised stock options and sold 25,000 shares of common stock on January 21, 2025, according to a Form 4 filing.

A Harmony Biosciences executive, Jeffrey Dierks, exercised stock options and sold shares, resulting in a net decrease in his direct holdings.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold 10,507 shares of common stock on January 15, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, sold 7,180 shares of common stock on January 13, 2025, for approximately $37.0399 per share.

Valor IV Pharma Holdings, a significant shareholder in Harmony Biosciences Holdings, has sold a portion of its common stock in two transactions.

Marshman Fund Trust II, a 10% owner of Harmony Biosciences Holdings, sold a significant number of common stock shares in early November 2024.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold 21,496 shares of common stock on October 29, 2024, as part of a pre-arranged trading plan.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold shares of common stock on October 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold 400 shares of common stock on October 1, 2024, while also exercising options for 400 shares at $24.

Chief Commercial Officer Jeffrey Dierks of Harmony Biosciences Holdings, Inc. reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., reports the vesting and subsequent tax withholding of restricted stock units.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, sold 35,846 shares of common stock on September 30, 2024, at an average price of $40.031, totaling approximately $1.43 million.

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold 200 shares of common stock at an average price of $40.045 on September 27, 2024, as part of a pre-arranged Rule 10b5-1 trading plan.

Gary Sender, a director at Harmony Biosciences Holdings, Inc., acquired 11,657 stock options on May 29, 2024.

Director Antonio J. Gracias acquired 8,870 stock options in Harmony Biosciences Holdings, Inc. on May 29, 2024.

Director Juan A. Sabater acquired 6,336 stock options in Harmony Biosciences Holdings, Inc. on May 29, 2024.

R. Mark Graf, a director at Harmony Biosciences Holdings, Inc., acquired 6,336 stock options on May 29, 2024.

Director Jack Nielsen acquired 6,336 stock options in Harmony Biosciences Holdings, Inc. on May 29, 2024.